Clinical trial
Bryostatin and Vincristine in B-Cell Malignancies
NCT00003166 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003166 |
|---|---|
| Title | Bryostatin and Vincristine in B-Cell Malignancies |
| Official title | A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | bryostatin 1, vincristine sulfate, laboratory biomarker analysis |
| Enrollment | 18 |
| Start date | May 1, 1998 |
| Primary completion | Jul 1, 2001 |
| First posted | Mar 19, 2004 |
| Last update posted | Jan 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: